Von Willebrand factor and JAK2V617F variant allele frequency predict thrombosis and bleeding in patients with myeloproliferative neoplasms
Annals of Hematology · 2025
DOI: 10.1007/s00277-025-06648-9 ↗Kurz gefasst
Fachartikel in der Zeitschrift Annals of Hematology, 2025. Verfasst von Ayala Gat und 8 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel. Hauptthemen laut MEDLINE: von Willebrand Factor, Thrombosis, Janus Kinase 2, Myeloproliferative Disorders. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Hebrew University of Jerusalem.
Abstract (Originalsprache)
Thrombosis is a major cause of morbidity and mortality in patients with myeloproliferative neoplasms (MPN), while bleeding is also common. Current thrombosis and bleeding risk stratification strategies are limited, creating a need for identification of novel risk factors to better predict these complications. We performed laboratory coagulation testing and driver mutation profiling from peripheral blood of patients with MPN. Patients’ history of comorbidities, hematological variables and thrombosis and/or bleeding events were collected retrospectively at the time of testing. Patients were then followed for a median of 3.3 years for incident events. 198 patients were included in the study. Thrombotic events occurred in 41% of the patients. Age, cardiovascular comorbidities and constitutional symptoms were significantly associated with thrombosis, as well as elevated von Willebrand Factor (vWF): Antigen, vWF: Activity and factor VIII levels. Elevated vWF: Antigen levels remained independent in multivariate analysis and were predictive of incident thrombosis. Bleeding events occurred in 26% of the patients. vWF: Activity ≤ 30%, vWF: Activity-to-antigen ratio of ≤ 0.7, a platelet count of ≥ 500*10 9 /L and JAK2 V617F variant allele frequency (VAF) of ≥ 50% were predictive of total (including minor) bleeding events. However, only JAK2 V617F VAF of ≥ 50% was predictive of major and clinically relevant non-major bleeding. Extreme thrombocytosis defined by a platelet count of ≥ 1000*10 9 /L was not associated with bleeding or acquired vWF syndrome. vWF profiling and JAK2 V617F VAF contribute to thrombosis and bleeding risk assessment in patients with MPNs and should be incorporated routinely at diagnosis and during follow-up.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.
- Department of Hematology, Hadassah Medical Center, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.
- Department of Hematology, Hadassah Medical Center, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel. eran.zimran@gmail.com.
Förderung
- Hebrew University of Jerusalem
Zitieren
APA
Gat, A., Kazoom, R., Shapira, I., Shai, E., Roth Jelinek, B., Buchman, N., Kalish, Y., Arad, A., & Zimran, E. (2025). Von Willebrand factor and JAK2V617F variant allele frequency predict thrombosis and bleeding in patients with myeloproliferative neoplasms. Annals of Hematology. https://doi.org/10.1007/s00277-025-06648-9
Vancouver
Gat A, Kazoom R, Shapira I, Shai E, Roth Jelinek B, Buchman N, et al. Von Willebrand factor and JAK2V617F variant allele frequency predict thrombosis and bleeding in patients with myeloproliferative neoplasms. Annals of Hematology. 2025. doi:10.1007/s00277-025-06648-9
BibTeX
@article{Gat2025,
author = {Gat, Ayala and Kazoom, Romi and Shapira, Inbal and Shai, Ela and Roth Jelinek, Batia and Buchman, Noa and Kalish, Yosef and Arad, Ariela and Zimran, Eran},
title = {Von Willebrand factor and JAK2V617F variant allele frequency predict thrombosis and bleeding in patients with myeloproliferative neoplasms},
journal = {Annals of Hematology},
year = {2025},
doi = {10.1007/s00277-025-06648-9}
}
EUVIMED